The Cambridge Alliance on Medicines Safety

Fixed-term: Funding for this post is available for 3 years

The Cambridge Alliance on Medicines Safety (CAMS; https://www.ats.cam.ac.uk/what-we-do/cambridge-alliance-medicines-safety) is delighted to be able to offer a Junior Research Fellowship in epigenetic drug safety and toxicology, starting Winter 2020.

The Cambridge Alliance on Medicines Safety (CAMS) was established in 2016 as a pre-competitive academic-industry partnership between AstraZeneca, GlaxoSmithKline, University of Cambridge and the MRC Toxicology Unit. A key aim is to expand and stimulate the science which underpins assessment of medicines safety and toxicology to advance the translational relevance of experimental safety studies.

This prestigious Junior Research Fellowship in epigenetic drug safety and toxicology aims to attract the very best early career researchers to Cambridge to develop a career in medicines safety science.

This Fellowship is intended to serve as a step towards independence in academic research and you are invited to apply with a one page research proposal covering your key aims under this fellowship. Successful applicants will have obtained a PhD in a relevant discipline and typically have had some postdoctoral experience.

We are seeking highly-motivated individuals with excellent communication skills and who are able to work effectively as part of a multi-disciplinary team. Given the opportunities enabled under the Alliance, applicants should also be able to demonstrate a specific interest in collaborating with industry to translate their research. Candidates should show exceptional initiative and demonstrate a capacity for innovation and independent thought, and be able to disseminate their scientific work actively to the scientific community as well as to the general public.

About Medicines Safety:

Medicines safety is an exciting area in which new science and technology are providing increased insight into how medicines or chemicals can adversely affect living organisms. It has the dual goal of ameliorating or avoiding harm to humans and of understanding fundamental processes in biology. This is achieved through the detection, detailed characterisation and understanding of adverse effects on biological systems, particularly those affecting humans.

Medicines safety is discipline agnostic: it draws on expertise from all areas of biomedical research and overlaps with pharmacology, biochemistry, epidemiology, bioinformatics, pathology, cell, developmental and systems biology.  Advances in molecular and computational systems are providing new mechanistic insight into our understanding of human relevant risk assessment which makes medicines safety an exciting field of research. Science in this field can range from computational simulations investigating the consequences of chemical exposure to molecular in vitro investigations of the harmful effects of chemicals and ultimately to in vivo and human exposure studies (including the safety of medicines in clinical trials)

All applications must be submitted online through the University's recruitment system.